BCR and leukemia: Our results also suggest that Hoxa9 is more potent than Hoxa10 in inducing CML myeloid blast crisis, as the Hoxa9+BCR/ABL mice developed leukemia with a significantly shorter latency than Hoxa10+BCR/ABL mice.